David C. Lubner

David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. Mr. Lubner most recently served as Executive Vice President and Chief Financial Officer of Ra Pharma, which was acquired by UCB in April 2020. Before joining Ra Pharma, he served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc. a biotechnology company, from its inception in 2006 to 2016, as Chief Financial Officer of and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company from 1999 until it was acquired by IMS Health in 2005 and as Vice President and Chief Financial Officer of and at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of multiple myeloma, was discovered.

Mr. Lubner currently serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), a company developing life-transforming therapies for patients with serious muscle diseases, Gemini Therapeutics, Inc.,(Nasdaq: GMTX) a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration, Vor Biopharma, Inc. (Nasdaq: VOR) a cell therapy company combining a novel patient engineering approach with targeted therapies to treat patients suffering from hematological malignancies, and several other private companies He previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019. Mr. Lubner is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.